Brought to you by 
Amyris, Sanofi-Aventis, and non-profits in malaria drug deal
08 Apr 2008
Executive Summary
Sanofi-Aventis, Amyris (synthetic biology for drug and chemical production), the Institute for OneWorld Health (iOWH), and the University of California, Berkeley have agreed to work together on the development, manufacturing, and commercialization of a semisynthetic artemisinin for use in malaria treatments.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amyris, Sanofi-Aventis, and non-profits in malaria drug deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice